M&A Deal Summary |
|
|---|---|
| Date | 2025-11-19 |
| Target | Factor Bioscience - Dual-CAR T Programs |
| Sector | Life Science |
| Buyer(s) | Tempest Therapeutics |
| Sellers(s) | Factor Bioscience |
| Deal Type | Divestiture |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2011 |
| Sector | Life Science |
| Employees | 24 |
| Revenue | 29M USD (2023) |
Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. Tempest Therapeutics is developing an inhibitor of TREX-1, a double-stranded DNA exonuclease that is designed to control activation of the cGAS/STING pathway, which is an innate immune response pathway that induces the production of IFN-?, a cytokine that is well-established to trigger the development of anti-tumor immunity. Tempest Therapeutic is based in Brisbane, California.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector: Life Science M&A | 2 of 2 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: Massachusetts M&A | 1 of 1 |
| Country: United States M&A | 2 of 2 |
| Year: 2025 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-03-29 |
Millendo Therapeutics
Ann Arbor, Michigan, United States Millendo Therapeutics is focused on developing novel treatments for endocrine diseases. Millendo Therapeutics creates distinct and transformative treatments for a wide range of diseases where there is a significant unmet medical need. Millendo Therapeutics is based in Ann Arbor, Michigan. |
Buy | - |
| Category | Company |
|---|---|
| Founded | 2011 |
| Sector | Life Science |
Factor Bioscience develops technologies for engineering cells to advance the study and treatment of disease. Factor Bioscience developed the fastest, highest-efficiency method for reprogramming somatic cells to a pluripotent stem-cell state, a key invention now recognized by several patents. This technology, which enables the production of patient-specific cells for transplantation, has wide-ranging applications in personalized regenerative medicine. Factor Bioscience was founded in 2011 and is based in Cambridge, Massachusetts.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector: Life Science M&A | 2 of 2 |
| Type: Divestiture M&A Deals | 2 of 2 |
| State: Massachusetts M&A | 2 of 2 |
| Country: United States M&A | 2 of 2 |
| Year: 2025 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-06-14 |
Novellus Therapeutics
Cambridge, Massachusetts, United States Novellus Therapeutics is a company developing next-generation engineered mesenchymal stem cell therapies using patented mRNA cell reprogramming and gene editing technologies. Novellus Therapeutics was founded in 2015 and is based in Cambridge, Massachusetts. |
Sell | $125M |
